Johns Hopkins Psychedelic Research Center @jhpsychedelics.bsky.social · 06/10/2026Just 2 days away from our online CME/CE course on psychedelic-assisted treatments, taught by our clinicians and expert scientists! Join us on Friday, Oct 9th from 8:45am-4:30pm ET. More info and registration link below! hopkinscme.cloud-cme.com/course/cours... 011
Johns Hopkins Psychedelic Research Center @jhpsychedelics.bsky.social · 02/10/2026What should clinicians know about psychedelic-assisted treatments? Learn from our experts and earn 6.5 CME/CE credits! 🔗 ⬇️ Fri, Oct. 9th | Online | 8:45am-4:30pm ET hopkinscme.cloud-cme.com/course/cours... 021
Johns Hopkins Psychedelic Research Center @jhpsychedelics.bsky.social · 02/10/2026If you have any questions about the study, please feel free to contact baeleighv@uvic.ca. 010
Johns Hopkins Psychedelic Research Center @jhpsychedelics.bsky.social · 02/10/2026During the interview, participants will have the opportunity to discuss their perspectives on current approaches to brain injury rehabilitation, the potential role of psychedelic-assisted therapies, and important ethical, clinical, and legal considerations related to their use. 110
Johns Hopkins Psychedelic Research Center @jhpsychedelics.bsky.social · 02/10/2026Participation in this study involves a brief pre-interview survey (less than 5 minutes) assessing attitudes toward psychedelics and demographic information, followed by a one-time Zoom interview (approximately 30–45 minutes). 110
Johns Hopkins Psychedelic Research Center @jhpsychedelics.bsky.social · 02/10/2026In collaboration with colleagues at University of Victoria, we are seeking healthcare professionals who work with individuals with brain injuries in rehabilitation settings to share their perspectives for our research study on the potential role of psychedelics in brain injury rehabilitation. 152
Johns Hopkins Psychedelic Research Center @jhpsychedelics.bsky.social · 30/09/2026Contact us at psilblock@jh.edu for more information or apply at jhmi.co1.qualtrics.com/jfe/form/SV_...jhmi.co1.qualtrics.comOnline Survey Software | Qualtrics Survey SolutionsThe most powerful, simple and trusted way to gather experience data. Start your journey to experience management and try a free account today. 000
Johns Hopkins Psychedelic Research Center @jhpsychedelics.bsky.social · 30/09/2026The study aims to understand the mechanisms in the brain responsible for the changes in perception induced by psilocybin. Participation will involve two dosing sessions at the Johns Hopkins Bayview campus. 111
Johns Hopkins Psychedelic Research Center @jhpsychedelics.bsky.social · 30/09/2026We are seeking healthy individuals to take part in a Johns Hopkins research study. The study will look at the effects of psilocybin, a psychedelic drug, with pindolol (a medication that blocks a serotonin receptor). 100
Reposted by Johns Hopkins Psychedelic Research CenterJohns Hopkins Psychedelic Research Center @jhpsychedelics.bsky.social · 02/09/2026What should clinicians know about psychedelic-assisted treatments? Join our online CME/CE course for an evidence-based introduction to psychedelic medicine covering patient engagement, emerging research, and the future of psychedelic-assisted care. Register: hopkinscme.cloud-cme.com/course/cours... 023
Johns Hopkins Psychedelic Research Center @jhpsychedelics.bsky.social · 24/09/2026Congratulations to Dr. Sayalı and the research team on this important achievement and exciting new direction for the Center. 010
Johns Hopkins Psychedelic Research Center @jhpsychedelics.bsky.social · 24/09/2026By integrating psychedelic pharmacology, personalized brain stimulation, and multimodal neuroscience, this work aims to advance both treatment development and our understanding of how brain-based interventions can reduce problematic alcohol use. 121
Johns Hopkins Psychedelic Research Center @jhpsychedelics.bsky.social · 24/09/2026Using fMRI and TMS-EEG, the study will also examine how this combined intervention changes the neural mechanisms underlying craving, cognitive control, and treatment response. 110
Johns Hopkins Psychedelic Research Center @jhpsychedelics.bsky.social · 24/09/2026This is the first study to investigate this combination for AUD, with rTMS targets individualized using fMRI to identify each participant’s brain circuitry involved in regulating alcohol craving. 110
Johns Hopkins Psychedelic Research Center @jhpsychedelics.bsky.social · 24/09/2026The study will test a novel treatment approach for alcohol use disorder (AUD) combining psilocybin with personalized repetitive transcranial magnetic stimulation (rTMS). 110
Johns Hopkins Psychedelic Research Center @jhpsychedelics.bsky.social · 24/09/2026We are thrilled to share a major milestone for the Johns Hopkins Center for Psychedelic and Consciousness Research: Ceyda Sayalı, PhD, has received an R01 award from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) — the first R01 awarded to an investigator at our Center. 1101
Johns Hopkins Psychedelic Research Center @jhpsychedelics.bsky.social · 23/09/2026Dr. David Yaden @existwell.bsky.social was interviewed for the @rollingstone.com article on the rise of psychedelic spirituality in America, weighing in on what the research actually shows about belief change after psychedelic experiences. www.rollingstone.com/culture/cult...rollingstone.comInside the New Psychedelic AwakeningPsychedelic have never been bigger. People are taking hallucinogens not for fun, but to find a deeper spiritual connection with the divine 051
Johns Hopkins Psychedelic Research Center @jhpsychedelics.bsky.social · 22/09/2026"It's better to start with stronger protections and adjust them as the evidence accumulates than to start with weaker protections and tighten them after harm." www.npr.org/2026/09/14/n...npr.orgPsychedelics get a hearing at FDAThe Trump administration has signaled it's behind the psychedelic renaissance, but there are still big questions about how these drugs will be administered once they are approved by the FDA. 020
Johns Hopkins Psychedelic Research Center @jhpsychedelics.bsky.social · 22/09/2026A clinical setting without these safeguards may introduce additional risk to patients. He urged the FDA to begin with strong safeguards in place and establish a clear protocol for relaxing them as evidence emerges. 120
Johns Hopkins Psychedelic Research Center @jhpsychedelics.bsky.social · 22/09/2026Referencing a JAMA Psychiatry meta-analysis on serious adverse events, Dr. Jacobs noted that even in a research setting where strong safeguards are in place, 4% of participants with pre-existing neuropsychiatric conditions experienced serious adverse events. 120
Johns Hopkins Psychedelic Research Center @jhpsychedelics.bsky.social · 22/09/2026NPR covered the FDA hearing on psychedelics last week. CPCR postdoctoral fellow Dr. Eddie Jacobs spoke to the risks of adverse events occurring outside of a research setting. 110
Johns Hopkins Psychedelic Research Center @jhpsychedelics.bsky.social · 21/09/2026Using a multi-study approach, CPCR researchers created and validated the Persisting Effects Questionnaire – Short Form (PEQ-SF), a scale that is more easily understood and reduces burden for study teams and participants. Read the paper here: journals.sagepub.com/doi/10.1177/...journals.sagepub.comSage Journals: Discover world-class researchSubscription and open access journals from Sage, the world's leading independent academic publisher. 020
Johns Hopkins Psychedelic Research Center @jhpsychedelics.bsky.social · 21/09/2026The Persisting Effects Questionnaire (PEQ) is a measure of self-reported positive and negative effects from psychedelic experiences. While commonly used, the PEQ has never been formally validated, and is time-intensive and complex for both participants and researchers. 120
Johns Hopkins Psychedelic Research Center @jhpsychedelics.bsky.social · 21/09/2026New paper – Validating and Creating a Short-Form of the Persisting Effects Questionnaire: A Measure of Positive and Negative Outcomes from Psychedelic Experiences 121
Johns Hopkins Psychedelic Research Center @jhpsychedelics.bsky.social · 18/09/2026Just 3 more weeks to sign up for our CME/CE course! The CPCR faculty led course will provide an evidence-based introduction to psychedelic medicine, covering patient engagement, emerging research, and the future of psychedelic-assisted care. Register at tinyurl.com/jhucme 001
Johns Hopkins Psychedelic Research Center @jhpsychedelics.bsky.social · 17/09/2026Representing Dr. David Yaden's (@existwell.bsky.social) lab at the CPCR & Hub at Oxford for Psychedelic Ethics (HOPE) — see Postdoc Eddie Jacobs, PhD from the FDA public hearing this week on the importance of safeguards based on standardized evidence on psychedelic treatments in clinical trials. 022
Johns Hopkins Psychedelic Research Center @jhpsychedelics.bsky.social · 16/09/2026In clinical trials, these risks can be much lower due to screening, medical oversight, and controlled environments, but they are not zero. At Johns Hopkins CPCR, we try to share a reminder about risks every year. Promising clinical signals deserve careful science, not hype. youtu.be/uhQj9FgGIwcyoutu.beRisks in Psychedelic Clinical Trials | Johns Hopkins Center for Psychedelic & Consciousness ResearchPsychedelics are not risk-free. In recreational settings, risks can include panic, impaired judgment, worsening of psychiatric symptoms, and persistent perceptual changes, all of which can be… 032
Johns Hopkins Psychedelic Research Center @jhpsychedelics.bsky.social · 16/09/2026Psychedelics are not risk-free. See our PSA video below. In recreational settings, risks can include panic, impaired judgment, worsening of psychiatric symptoms, and persistent perceptual changes, all of which can be compounded by unknown dosing. 131
Johns Hopkins Psychedelic Research Center @jhpsychedelics.bsky.social · 16/09/2026Postdoctoral Research Fellow, Eddie Jacobs, PhD, spoke to how the evidence on psychedelic treatments comes from clinical trials, so those safeguards should be used for initial roll-out, to be adjusted based on data collected in a standardized manner and comparable to other treatments & substances. 021
Johns Hopkins Psychedelic Research Center @jhpsychedelics.bsky.social · 16/09/2026CPCR researchers at the Yaden Lab attended the FDA public hearing for the potential of psychedelics for therapeutic use. 121
Johns Hopkins Psychedelic Research Center @jhpsychedelics.bsky.social · 14/09/2026Join the Psychedelic Archives Project guest speaker series with Dr. Charles Nichols this Wednesday through the zoom link, no sign up is required. jhubluejays.zoom.us/j/92622903856 022
Johns Hopkins Psychedelic Research Center @jhpsychedelics.bsky.social · 09/09/2026Interested in experiencing psychedelics under professional supervision? We are seeking healthy adults ages 21-65 to participate in a clinical trial on the effects of psilocybin and its interaction with other medications. Apply at jhmi.co1.qualtrics.com/jfe/form/SV_.... 010
Johns Hopkins Psychedelic Research Center @jhpsychedelics.bsky.social · 04/09/2026Dr. Charles Nichols joins us for the Psychedelic Archives Project guest speaker series, presenting “Psychedelic Use in Preconquest Mesoamerica: Probably Not What You’ve Been Told”, on Wednesday, September 16, 2026, at 4:30pm ET. Join on this Zoom link: jhubluejays.zoom.us/j/92622903856 172
Johns Hopkins Psychedelic Research Center @jhpsychedelics.bsky.social · 02/09/2026Delivering a comprehensive review of the current knowledge and evidence for the use of psychedelics in practice, this textbook seeks to further the field of psychedelic science and build more momentum in this exciting new era of research and clinical care! Available at: www.appi.org/Products/Gen...appi.orghttps://www.appi.org/Products/General-Interest/Psychedelics 000
Johns Hopkins Psychedelic Research Center @jhpsychedelics.bsky.social · 02/09/2026CPCR Associate Director, Dr. Albert Garcia-Romeu, alongside editors Dr. Scott Aaronson at Sheppard Pratt and Dr. Trisha Suppes at Stanford Medicine, recently published Psychedelics: Transforming Psychiatry. 100
Johns Hopkins Psychedelic Research Center @jhpsychedelics.bsky.social · 02/09/2026What should clinicians know about psychedelic-assisted treatments? Join our online CME/CE course for an evidence-based introduction to psychedelic medicine covering patient engagement, emerging research, and the future of psychedelic-assisted care. Register: hopkinscme.cloud-cme.com/course/cours... 023
Johns Hopkins Psychedelic Research Center @jhpsychedelics.bsky.social · 01/09/2026How comparable is psilocybin and Δ9-THC? Could the use of Δ9-THC help with the blinding problem we face in psychedelic trials? Check out our latest findings from @fredbarrettphd.bsky.social and colleagues. 021
Johns Hopkins Psychedelic Research Center @jhpsychedelics.bsky.social · 01/09/2026Johns Hopkins CPCR is hosting a satellite event for SfN 2026: Advancing Cross-Species Research in Psychedelic Neurosciences. Friday, November 13, 2026 · 9:00 a.m. – 7:00 p.m. Marriott Marquis Washington, DC Learn more at www.eventbrite.com/e/advancing-... 010
Johns Hopkins Psychedelic Research Center @jhpsychedelics.bsky.social · 21/08/2026This week, NPR featured novel data on the Oregon psilocybin services program. Associate Center Director, Dr. Albert Garcia-Romeu, weighed in on the newly published safety and mental health outcomes. See the digital story here: www.npr.org/2026/08/19/n...npr.orgA real-world study of Oregon's nonmedical psilocybin program shows promiseOregon was the first state to establish a legalized and regulated psilocybin industry. Since then, thousands have tried magic mushrooms. Here is the latest data from the state's real-life experiment. 062
Johns Hopkins Psychedelic Research Center @jhpsychedelics.bsky.social · 12/08/2026Dr. Azin Bekhrad, co-founder and psychiatrist at the Johns Hopkins Clinic for Post-Psychedelic Difficulties, spoke with Scientific American on the first year of the clinic: www.scientificamerican.com/article/firs...scientificamerican.comPsychedelic trips can go wrong—new clinics are there to helpAs psychedelic therapies expand, new clinics treat uncommon long-term harms 043
Johns Hopkins Psychedelic Research Center @jhpsychedelics.bsky.social · 06/08/2026Contact us at psilblock@jh.edu or apply at jhmi.co1.qualtrics.com/jfe/form/SV_... Postdoc Contact Information: Zarmeen Zahid, Ph.D., zzahid2@jh.edu Principal Investigator: Sandeep Nayak, M.D. Protocol: IRB00478908jhmi.co1.qualtrics.comOnline Survey Software | Qualtrics Survey SolutionsThe most powerful, simple and trusted way to gather experience data. Start your journey to experience management and try a free account today. 010
Johns Hopkins Psychedelic Research Center @jhpsychedelics.bsky.social · 06/08/2026The study aims to understand the mechanisms in the brain responsible for the changes in perception induced by psilocybin. Participation will involve two dosing sessions at the Johns Hopkins Bayview campus. 110
Johns Hopkins Psychedelic Research Center @jhpsychedelics.bsky.social · 06/08/2026We are seeking healthy individuals to take part in a Johns Hopkins research study. The study will look at the effects of psilocybin, a psychedelic drug, with pindolol (a medication that blocks a serotonin receptor). 130
Johns Hopkins Psychedelic Research Center @jhpsychedelics.bsky.social · 04/08/2026What should psychedelic science take - and not take - from other disciplines? Join us in celebrating the book launch of The Oxford Handbook of Psychedelic, Religious, Spiritual, and Mystical Experiences on Wed, Aug 5th from 10am-2pm ET. Attend in-person in Washington DC or virtually on Zoom. 033
Johns Hopkins Psychedelic Research Center @jhpsychedelics.bsky.social · 28/07/2026Dr. David Yaden shares insights and safety considerations for Oregon’s psilocybin services program with the Oregon Capital Chronicle: oregoncapitalchronicle.com/2026/06/30/g...oregoncapitalchronicle.comGrowing scope of Oregon psilocybin program raises safety concerns, study says • Oregon Capital ChronicleSome of the top reasons people use Oregon's program include health and wellness, changes in perspective and "expanded concsiousness." 000
Johns Hopkins Psychedelic Research Center @jhpsychedelics.bsky.social · 27/07/2026Do you live with chronic low back pain and depression? You’re not alone. Our research team at Johns Hopkins is studying whether psilocybin may help with pain and mood. If you’d like to learn more or see if you qualify, visit the link below. hopkinspsychedelic.org/backpain 021
Johns Hopkins Psychedelic Research Center @jhpsychedelics.bsky.social · 14/07/2026Can Psychedelics Treat Addiction? Dr. Albert Garcia-Romeu was interviewed by Dr. Jonathan Avery on Thriving with Addiction podcast, discussing his research on the effects of psychedelics on addiction:podcasts.apple.comCan Psychedelics Treat Addiction? with Dr. Albert Garcia-RomeuPodcast Episode · Thriving with Addiction with Dr. Jonathan Avery · July 14 · 40m · Video 010
Johns Hopkins Psychedelic Research Center @jhpsychedelics.bsky.social · 07/07/2026The CPCR is seeking a full-time Clinical Program Coordinator to join our team and support clinical trials and studies in the field of psychedelic science. Learn more and apply here: hiring.jhu.edu/careers/job/... 011
Johns Hopkins Psychedelic Research Center @jhpsychedelics.bsky.social · 06/07/2026In it, he discussed the role of autobiographically salient music on emotion, altered states of consciousness, well-being, and EEG brain activity. Published results coming soon! 110
Johns Hopkins Psychedelic Research Center @jhpsychedelics.bsky.social · 06/07/2026Last month, CPCR Postdoctoral Research Fellow, David S. Rosen @docdurdur.bsky.social, presented neural and behavioral results from our music and psilocybin, non-drug, immersive listening pilot study at the Society for the Neuroscience of Creativity’s 2026 Conference in Philadelphia. 130